Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2613

1.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
2.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F.

J Clin Oncol. 2005 Apr 20;23(12):2822-30. Erratum in: J Clin Oncol. 2005 Aug 20;23(24):5851. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

3.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
4.

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C.

J Clin Oncol. 1997 Aug;15(8):2966-73.

PMID:
9256141
5.
8.

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.

Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J.

Clin Ther. 1996 May-Jun;18(3):508-18. Corrected and republished in: Clin Ther. 1996 Jul-Aug;18(4):778-88.

PMID:
8829027
9.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
11.

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.

Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J.

Clin Ther. 1996 Jul-Aug;18(4):778-88.

PMID:
8879903
12.

[Recent improvements in antiemetic therapy].

Roila F, Palladino MA, Ciccarese G, Basurto C.

Tumori. 1997;83(2 Suppl):S3-14. Review. Italian.

PMID:
9235727
14.

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.

Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V.

Curr Med Res Opin. 2007 Mar;23(3):533-43.

PMID:
17355735
15.

Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.

Treish I, Shord S, Valgus J, Harvey D, Nagy J, Stegal J, Lindley C.

Support Care Cancer. 2003 Aug;11(8):516-21. Epub 2003 Jun 27.

PMID:
12836088
16.
17.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
18.
20.
Items per page

Supplemental Content

Write to the Help Desk